EXELIXIS, INC. — Director's Dealing 2025

May 17, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EXELIXIS, INC. (EXEL)
CIK: 0000939767
Period of Report: 2025-05-15

Reporting Person: Peterson Amy C. (EVP Prod Dev & Med Aff & CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-05-15	Common Stock	F	8303	$44.65	Disposed	498169	Direct
2025-05-16	Common Stock	M	40000	$21.75	Acquired	538169	Direct
2025-05-16	Common Stock	S	72776	$45.47	Disposed	465393	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-16	Option (right to buy)	$21.75	M	40000	Disposed	2030-08-23	Common Stock (40000)	Direct

Footnotes

F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded February 23, 2024.

F2: Includes 453,166 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock.

F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $45.08 to $46.44. Reporting Person undertakes to provide Exelixis, Inc., any security
holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in
footnote 3 to this Form 4.

F4: The option, representing the right to purchase a total of 160,000 shares of Common Stock, 40,000 shares became exercisable on August 24, 2024 and the remainder will become fully exercisable on August 24, 2027.